Ascentage hopes to become a new force in BTK.
ApexOnco Front Page
Recent articles
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
Subcutaneous Opdivo joins Tecentriq Hybreza to round out 2024.
The synthetic lethality specialist licenses in its second ADC in six months.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
US approval gives Pfizer the first and second-line settings.
